Managing Late Periprosthetic Fluid Collections (Seroma) in Patients with Breast Implants: A Consensus Panel Recommendation and Review of the Literature

Bengtson, Bradley P.; Brody, Garry S.; Brown, Mitchell H.; Glicksman, Caroline; Hammond, Dennis C.; Kaplan, Hilton M.; Maxwell, G. Patrick; Oefelein, Michael G.; Reisman, Neal R.; Spear, Scott L.; Jewell, Mark L.

doi:10.1097/prs.0b013e318217fdb0

Cited by 100 publications

(85 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bengston and colleagues presented a literature review and a consensus panel recommendation about late periprosthetic seromas in patients with breast implants (22).…”

Section: Late Seromasmentioning

confidence: 99%

How to prevent complications in breast augmentation

Nava¹,

Rancati²,

Angrigiani³

et al. 2017

Gland Surg.

View full text Add to dashboard Cite

Abstract:No high-level evidences about the best technique or the best implant to use for obtaining the best outcomes in aesthetic breast augmentation, with low complications and re-interventions rates exist from available literature. In this paper we present the actual best evidence about the etiopathogenesis of main complications in aesthetic breast augmentation, identifying some basic rules to follow in order to reduce complication rates in our daily activity, minimizing re-interventions, obtaining long lasting results and high women's satisfaction levels.

show abstract

“…Bengston and colleagues presented a literature review and a consensus panel recommendation about late periprosthetic seromas in patients with breast implants (22).…”

Section: Late Seromasmentioning

confidence: 99%

How to prevent complications in breast augmentation

Nava¹,

Rancati²,

Angrigiani³

et al. 2017

Gland Surg.

View full text Add to dashboard Cite

show abstract

“…Finally, the fluid is malignant if cancer cells exist (9). Non-Hodgkin T cell lymphoma of the breast, currently known as anaplastic large T cell lymphoma, can present as a late seroma following breast augmentation (9). The incidence of anaplastic large T cell lymphoma is extremely low and is estimated to be 1 per 1 million women per year (10).…”

Section: Discussionmentioning

confidence: 99%

“…The effusion is inflammatory if it comprises predominantly white blood cells. Finally, the fluid is malignant if cancer cells exist (9). Non-Hodgkin T cell lymphoma of the breast, currently known as anaplastic large T cell lymphoma, can present as a late seroma following breast augmentation (9).…”

Section: Discussionmentioning

confidence: 99%

Late Seroma Formation During Pregnancy: Case Report and Review of the Literature

Steen

Gauvin

Meathrel

2015

Plastic Surgery Case Studies

View full text Add to dashboard Cite

Breast augmentation surgery is the most common cosmetic surgery in the United States, and seroma is a known complication of breast augmentation. However, late seroma is a rare event and is most associated with textured implants. A 29-year-old woman with a remote history of breast implantation presented to the plastic surgery clinic for evaluation of a swollen breast, which began 24 h postpartum. Magnetic resonance imaging revealed peri-implant fluid maintained within the fibrous capsule. The patient was managed conservatively and the swelling self-resolved without recurrence. The authors report the first known case of a late seroma associated with pregnancy, occurring nine years postoperatively.

show abstract

“…This has made it difficult to analyze the cases in the literature. Initial management of a late-onset seroma or peri-implant mass associated with a breast implant has evolved into a more standardized approach (11)(12)(13). In an attempt to gather consistent data from case to case for analysis, the FDA and the American Society of Plastic Surgeons recommend collecting and reporting specific data to their registry (Table 2) (5).…”

Section: Discussionmentioning

confidence: 99%

“…These findings also suggested extracapsular implant rupture. Ultrasound-guided aspiration yielded 1200 mL of light-yellow fluid, which was sent for cytology and culture as recommended in the literature (11)(12)(13). Cytology revealed features consistent with ALCL and CD30 positivity, and was negative for ALK-1.…”

Section: Abstract: Anaplastic Large Cell Lymphoma; Breast Implant; Lmentioning

confidence: 99%

Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease

Weathers¹,

Wolfswinkel²,

Hatef³

et al. 2013

CAN J PLAST SURG

View full text Add to dashboard Cite

A naplastic large cell lymphoma (ALCL) is the subject of increasing scrutiny among plastic surgeons and the public. Accounting for only 3% of all non-Hodgkin's lymphoma and 0.5% of all breast cancers, ALCL is rare (1-4). Multiple reports have highlighted a possible relationship between ALCL in the breast and breast implants. In January 2011, the United States Food and Drug Administration (FDA) published an investigation of ALCL and breast implants, which concluded that there is a possible association between breast implants and ALCL; however, the low incidence of ALCL -0.1 to 0.3 per 100,000 -would make proving causality exceedingly difficult (5,6). A multidisciplinary panel of experts reached a similar conclusion (7,8), suggesting an association without a causal relationship between breast implants and ALCL. Other than asserting that an association between implants and ALCL likely exists, no clear consensus regarding ALCL and breast implants has emerged.In the literature, contributing factors for implant-associated ALCL have not been established. Of the known cases of ALCL associated with implants, both saline and silicone implants have been documented (5). It has been reported in patients both receiving implants for cosmetic purposes and for reconstruction secondary to cancer (9). Time to presentation after placement of breast implants has ranged from one to 23 years, and patients' age has ranged from 28 to 87 years (6). The most consistent association is that all cases of breast implantassociated ALCL in which cytology is known, demonstrate strong CD30 positivity and are anaplastic lymphoma kinase-1 (ALK-1) negative (5,7,10). Continued vigilance in reporting cases is needed to further elucidate possible contributing factors.The majority of what is known about ALCL is derived from case reports. The data from these reports are somewhat limited in that not all contain complete details. A standard work-up for suspected new cases has been recommended by the FDA to ensure that all pertinent information is obtained from each case in the future (5). This will ensure accurate and complete information, and further the study of ALCL and its relationship with breast implants. Using these new recommendations, we present one case of implant-associated ALCL that presented to our facility. Case presentationA 44-year-old female underwent bilateral subglandular breast augmentation in 2005 in Mexico with 410 mL CUI round-textured silicone implants (Allergan, USA) through an inframammary approach. The patient experienced no immediate postoperative complications and had an uneventful course until her presentation to the Ben Taub General Hospital (Texas, USA) seven years after surgery.In 2012, the patient presented to the Ben Taub General Hospital emergency department complaining of progressive left breast swelling and erythema for three months. The patient denied fever, chills or symptoms of systemic toxicity. The patient had no recent history of trauma or breastfeeding. On presentation, the patient was afebrile and hemodynamical...

show abstract

Managing Late Periprosthetic Fluid Collections (Seroma) in Patients with Breast Implants: A Consensus Panel Recommendation and Review of the Literature

Cited by 100 publications

References 29 publications

How to prevent complications in breast augmentation

How to prevent complications in breast augmentation

Late Seroma Formation During Pregnancy: Case Report and Review of the Literature

Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease

Contact Info

Product

Resources

About